Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists

BACKGROUND: Recent approvals for novel agents such as the small molecule Janus kinase inhibitors (JAKi), combined with the advent of biosimilars has widened the gamut of available therapeutic options in the treatment of rheumatoid arthritis (RA). This combined with the introduction of mandatory non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Choquette, Denis, Chan, Jonathan, Bardi, Mohammad, Whiskin, Carolyn, Torani, Gabriel, Smith, Brennan K., Sihota, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455126/
https://www.ncbi.nlm.nih.gov/pubmed/34621449
http://dx.doi.org/10.18549/PharmPract.2021.3.2377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455126/
https://www.ncbi.nlm.nih.gov/pubmed/34621449
http://dx.doi.org/10.18549/PharmPract.2021.3.2377

Ejemplares similares